It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Endothelial cells (ECs) are highly glycolytic, but whether they generate glycolytic intermediates via gluconeogenesis (GNG) in glucose-deprived conditions remains unknown. Here, we report that glucose-deprived ECs upregulate the GNG enzyme PCK2 and rely on a PCK2-dependent truncated GNG, whereby lactate and glutamine are used for the synthesis of lower glycolytic intermediates that enter the serine and glycerophospholipid biosynthesis pathways, which can play key roles in redox homeostasis and phospholipid synthesis, respectively. Unexpectedly, however, even in normal glucose conditions, and independent of its enzymatic activity, PCK2 silencing perturbs proteostasis, beyond its traditional GNG role. Indeed, PCK2-silenced ECs have an impaired unfolded protein response, leading to accumulation of misfolded proteins, which due to defective proteasomes and impaired autophagy, results in the accumulation of protein aggregates in lysosomes and EC demise. Ultimately, loss of PCK2 in ECs impaired vessel sprouting. This study identifies a role for PCK2 in proteostasis beyond GNG.
This study reports a unexpected role in endothelial cells (ECs) for PCK2 in proteostasis, independent of its gluconeogenic activity. Perturbation of this role likely contributed to the angiogenic defects observed in ECs with reduced PCK2 levels.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 KU Leuven, Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Cancer Biology, VIB, Laboratory of Angiogenesis and Vascular Metabolism, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Droia Ventures, Zaventem, Belgium (GRID:grid.11486.3a)
2 KU Leuven, Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Cancer Biology, VIB, Laboratory of Angiogenesis and Vascular Metabolism, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); CNRS, Nantes, France (GRID:grid.463945.9) (ISNI:0000 0004 0385 1628)
3 KU Leuven, Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Cancer Biology, VIB, Laboratory of Angiogenesis and Vascular Metabolism, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); University of Malaga, Dept. Molecular Biology and Biochemistry, Fac. Science, Malaga, Spain (GRID:grid.10215.37) (ISNI:0000 0001 2298 7828)
4 KU Leuven, Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Cancer Biology, VIB, Laboratory of Angiogenesis and Vascular Metabolism, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040)
5 KU Leuven, Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Cancer Biology, VIB, Laboratory of Angiogenesis and Vascular Metabolism, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Aarhus University, Aarhus Institute of Advanced Studies (AIAS), Department of Biomedicine, Aarhus, Denmark (GRID:grid.7048.b) (ISNI:0000 0001 1956 2722)
6 KU Leuven, Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Cancer Biology, VIB, Laboratory of Angiogenesis and Vascular Metabolism, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Novartis Ireland, Dublin, Ireland (GRID:grid.496862.7) (ISNI:0000 0004 0544 6263)
7 KU Leuven, Laboratory of Lipid Metabolism and Cancer, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
8 KU Leuven, Metabolomics Core Facility, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Cancer Biology, VIB, Metabolomics Core Facility, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040)
9 KU Leuven, Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Cancer Biology, VIB, Laboratory of Angiogenesis and Vascular Metabolism, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Metaptys NV/Droia Labs, Leuven, Belgium (GRID:grid.11486.3a)
10 KU Leuven, Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Cancer Biology, VIB, Laboratory of Angiogenesis and Vascular Metabolism, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Khalifa University of Science and Technology, Center for Biotechnology, Abu Dhabi, United Arab Emirates (GRID:grid.440568.b) (ISNI:0000 0004 1762 9729)